| cPLA2 is phosphorylated and activated by MAP kinase LL Lin, M Wartmann, AY Lin, JL Knopf, A Seth, RJ Davis Cell 72 (2), 269-278, 1993 | 2341 | 1993 |
| Discovery of 3-(2, 6-dichloro-3, 5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor … V Guagnano, P Furet, C Spanka, V Bordas, M Le Douget, C Stamm, ... Journal of medicinal chemistry 54 (20), 7066-7083, 2011 | 517 | 2011 |
| CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors SR Vora, D Juric, N Kim, M Mino-Kenudson, T Huynh, C Costa, ... Cancer cell 26 (1), 136-149, 2014 | 472 | 2014 |
| AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity P Traxler, PR Allegrini, R Brandt, J Brueggen, R Cozens, D Fabbro, ... Cancer Research 64 (14), 4931-4941, 2004 | 412 | 2004 |
| Control of MAP kinase activation by the mitogen-induced threonine/tyrosine phosphatase PAC1 Y Ward, S Gupta, P Jensen, M Wartmann, RJ Davis, K Kelly Nature 367 (6464), 651-654, 1994 | 412 | 1994 |
| Epothilones and related structures-a new class of microtubule inhibitors with potent in vivo antitumor activity KH Altmann, M Wartmann, T O'Reilly Biochimica et Biophysica Acta (BBA)/Reviews on Cancer 1470 (3), M79-M91, 2000 | 353 | 2000 |
| The native structure of the activated Raf protein kinase is a membrane-bound multi-subunit complex. M Wartmann, RJ Davis Journal of Biological Chemistry 269 (9), 6695-6701, 1994 | 348 | 1994 |
| Isolation and characterization of two growth factor-stimulated protein kinases that phosphorylate the epidermal growth factor receptor at threonine 669 IC Northwood, FA Gonzalez, M Wartmann, DL Raden, RJ Davis Journal of Biological Chemistry 266 (23), 15266-15276, 1991 | 283 | 1991 |
| Extended kinase profile and properties of the protein kinase inhibitor nilotinib PW Manley, P Drueckes, G Fendrich, P Furet, J Liebetanz, ... Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1804 (3), 445-453, 2010 | 264 | 2010 |
| The biology and medicinal chemistry of epothilones M Wartmann, K Altmann Current Medicinal Chemistry-Anti-Cancer Agents 2 (1), 123-148, 2002 | 260 | 2002 |
| The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide M Wartmann, D Campbell, A Subramanian, SH Burstein, RJ Davis FEBS letters 359 (2-3), 133-136, 1995 | 241 | 1995 |
| Biosynthesis and posttranslational modifications of protein kinase C in human breast cancer cells C Borner, I Filipuzzi, M Wartmann, U Eppenberger, D Fabbro Journal of Biological Chemistry 264 (23), 13902-13909, 1989 | 208 | 1989 |
| Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib PW Manley, N Stiefl, SW Cowan-Jacob, S Kaufman, J Mestan, ... Bioorganic & medicinal chemistry 18 (19), 6977-6986, 2010 | 201 | 2010 |
| Chemical synthesis and biological properties of pyridine epothilones KC Nicolaou, R Scarpelli, B Bollbuck, B Werschkun, MMA Pereira, ... Chemistry & biology 7 (8), 593-599, 2000 | 197 | 2000 |
| STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake K Pietras, M Stumm, M Hubert, E Buchdunger, K Rubin, CH Heldin, ... Clinical cancer research 9 (10), 3779-3787, 2003 | 184 | 2003 |
| Acentrosomal spindle organization renders cancer cells dependent on the kinesin HSET J Kleylein-Sohn, B Pöllinger, M Ohmer, F Hofmann, EA Nigg, ... Journal of cell science 125 (22), 5391-5402, 2012 | 179 | 2012 |
| The Ret receptor tyrosine kinase pathway functionally interacts with the ERα pathway in breast cancer A Boulay, M Breuleux, C Stephan, C Fux, C Brisken, M Fiche, ... Cancer research 68 (10), 3743-3751, 2008 | 159 | 2008 |
| Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805 F Baffert, CH Régnier, A De Pover, C Pissot-Soldermann, GA Tavares, ... Molecular cancer therapeutics 9 (7), 1945-1955, 2010 | 149 | 2010 |
| Mitogen-activated protein (MAP) kinase phosphorylation of MAP kinase kinase: determination of phosphorylation sites by mass spectrometry and site-directed mutagenesis SJ Mansour, KA Resing, JM Candi, AS Hermann, JW Gloor, KR Herskind, ... The Journal of Biochemistry 116 (2), 304-314, 1994 | 137 | 1994 |
| A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients R Tiedt, E Degenkolbe, P Furet, BA Appleton, S Wagner, J Schoepfer, ... Cancer research 71 (15), 5255-5264, 2011 | 131 | 2011 |
